132019-54-6

Basic information

• Product Name: Monatepil
• Synonyms: Monatepil;N-(6,11-Dihydrobenzo[c][1]benzothiepin-11-yl)-4-[4-(4-fluorophenyl)piperazin-1-yl]butanamide;N-(6,11-Dihydrodibenzo[b,e]thiepin-11-yl)-4-(4-(4-fluorophenyl)piperazin-1-yl)butanamide
• CAS NO: 132019-54-6
• Molecular Formula: C28H30FN3OS
• Molecular Weight: 475.62
• Mol File: 132019-54-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 682 °C at 760 mmHg
• Flash Point: 366.3 °C
• Appearance: /
• Density: 1.28g/cm³
• CAS DataBase Reference: Monatepil(CAS DataBase Reference)
• NIST Chemistry Reference: Monatepil(132019-54-6)
• EPA Substance Registry System: Monatepil(132019-54-6)

Safety Data

• Hazardous Substances Data: 132019-54-6(Hazardous Substances Data)

Usage

Uses

Antianginal; antihypertensive.

InChI:InChI=1/C28H30FN3OS/c29-22-11-13-23(14-12-22)32-18-16-31(17-19-32)15-5-10-27(33)30-28-24-7-2-1-6-21(24)20-34-26-9-4-3-8-25(26)28/h1-4,6-9,11-14,28H,5,10,15-20H2,(H,30,33)

Upstream product

• 1745-53-5 11-amino-6,11-dihydrodibenzothiepin 
• 103379-37-9 4-Chloro-N-(5,11-dihydro-10-thia-dibenzo[a,d]cyclohepten-5-yl)-butyramide 
• 2252-63-3 1-(4-Fluorophenyl)piperazine 

Related news

Inhibitory Effect of Monatepil (cas 132019-54-6) Maleate on Acyl-CoA:Cholesterol Acyltransferase Activity in the Liver of Cholesterol-Fed Japanese Monkeys07/28/2019

We have previously demonstrated that monatepil maleate, AJ-2615, a new calcium antagonist endowed with α1-adrenoceptor blocking property, has antiatherosclerotic and plasma lipid-lowering effects in Japanese monkeys fed on a cholesterol-rich diet. To clarify the mechanisms on plasma lipid-lower...detailed

Relevant articles and documents

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

Method for treating resistant hypertension

A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.

A New Class of Calcium Antagonists. 2. Synthesis and Biological Activity of 11-butyryl>amino>-6,11-dihydrodibenzothiepin Maleate and related Compounds

A series of -6,11-dihydrodibenzothiepins and -5H-dibenzocycloheptenes and related compounds were synthesized and evaluated for calcium antagonistic activity by calcium-induced constriction of potassium-depolarized rat aorta.Semiempirical molecular orbital calculations of the dibenzotricyclic systems indicated that calcium antagonistic activity increased with a decrease of the angle between the planes of the two phenyl rings.AM1 net charge calculations showed that a neutral or positive charge distribution in the bridge portion was necessary for activity. 11-butyryl> amino >-6,11-dihydrodibenzothiepin maleate (16, AJ-2615) showed a more gradual and longer lasting antihypertensive effect than diltiazem and nifedipine in spontaneously hypertensive rats (SHR) administered orally.Compound 16 also possessed antianginal effects in methacholine-induced ST elevation and vasopressin-induced ST depression tests in rats.The alteration of the dibenzotricyclic system of 16 to 5H-dibenzocycloheptene (19, 5-butyryl>amino>-5H-dibenzocycloheptene) resulted in selectivity for cardiac tissue over vascular tissue, thereby conferring antianginal activity without an effect on blood pressure.Antianginal potencies of 16 and 19 were equal to or somewhat more potent than those of diltiazem.